Search results for ADA2026
ADA2026 community
One keyword maps to one global community path.
People
Not Found
Tweets including ADA2026
With #ADA2026# right around the corner, now’s the perfect time to familiarize yourself with the latest in ketone monitoring with our free, CME-accredited masterclass series; designed to enhance your confidence and decision-making:
Show more
The conversations at #ADA2026# are helping to build a new era of care.
That’s a wrap on #ADA2026#. It left us with important reminders about why science matters and who it’s for. #WeAreLilly#
NEW Phase 3 data today at #ADA2026#: Lilly's investigational triple agonist met all primary endpoints in TRIUMPH-1. Patients on the 12 mg dose lost an avg of 70 pounds (28.3%) over 80 weeks. Read more:
Show more
New data: Our oral GLP-1 delivered superior A1C control and weight loss across three clinical trials. Read more: #ADA2026#
Women at every stage of menopause — pre, peri and post — experienced meaningful weight loss in post-hoc analyses of two studies of one of our obesity medicines presented at #ADA2026#. Up to 30 pounds lost on the highest dose at 72 weeks. Read more:
Show more
Adults with type 2 diabetes on our investigational triple agonist saw significant A1C reductions at 40 weeks in the TRANSCEND-T2D-1 trial. Results presented today at #ADA2026# and published simultaneously in @TheLancet. Read more:
Show more
In addition to weight loss, our investigational triple agonist reduced moderate-to-severe obstructive sleep apnea severity by an average 61 percent on the 9 mg dose in the TRIUMPH-1 study. Presented today at #ADA2026#. Read more:
Show more
We’re focused on advancing science to help people achieve meaningful weight loss — and the additional health benefits that may come with it. On Saturday we’re presenting data from the TRIUMPH-1 study of our investigational triple agonist at #ADA2026#. Stay tuned.
Show more
It's not just about weight. In TRIUMPH-1, Lilly’s investigational triple agonist reduced knee osteoarthritis pain by an average of 73% at the 12 mg dose and moderate-to-severe obstructive sleep apnea severity by an average of 61% at the 9 mg dose for people living with obesity. Presented today at #ADA2026#. Read more:
Show more
